We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+9.54%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$109B
AUM Growth
+$10.1B
Cap. Flow
+$2.06B
Cap. Flow %
1.89%
Top 10 Hldgs %
23.41%
Holding
4,156
New
227
Increased
1,649
Reduced
1,885
Closed
242

Sector Composition

Rank Sector Weight
1 Technology 12.52%
2 Healthcare 9.35%
3 Financials 9.23%
4 Industrials 6.82%
5 Consumer Discretionary 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BWIN
2626
Baldwin Insurance Group
BWIN
$2.93B
$730K ﹤0.01%
29,044
+4,023
+16% +$111K
NAVI icon
2627
Navient
NAVI
$853M
$728K ﹤0.01%
44,276
+1,271
+3% +$20.1K
SMCI icon
2628
Super Micro Computer
SMCI
$25.7B
$726K ﹤0.01%
88,450
-420
-0.5% -$3.2K
MNDY icon
2629
monday.com
MNDY
$3.73B
$723K ﹤0.01%
5,928
-942
-14% -$98K
IGMS
2630
DELISTED
IGM Biosciences
IGMS
$723K ﹤0.01%
42,516
+1,883
+5% +$37.7K
VISN
2631
Vistance Networks Inc
VISN
$2.65B
$722K ﹤0.01%
98,254
+7,804
+9% +$75.3K
UAA icon
2632
Under Armour
UAA
$2.31B
$722K ﹤0.01%
71,045
+20,161
+40% +$174K
BTU icon
2633
Peabody Energy
BTU
$3.06B
$720K ﹤0.01%
27,269
-11,675
-30% -$321K
PBT
2634
Permian Basin Royalty Trust
PBT
$1.6B
$720K ﹤0.01%
28,566
+18,251
+177% +$377K
IBDV icon
2635
iShares iBonds Dec 2030 Term Corporate ETF
IBDV
$3.3B
$719K ﹤0.01%
34,588
-531
-2% -$10.9K
APG icon
2636
APi Group
APG
$18.9B
$719K ﹤0.01%
57,323
+2,105
+4% +$24.3K
GILD icon
2637
CALL
Gilead Sciences
GILD
$170B
$718K ﹤0.01%
33,700
-34,700
-51% -$2.75M
VRAY
2638
DELISTED
ViewRay, Inc.
VRAY
$716K ﹤0.01%
159,875
-1,000
-0.6% -$4.35K
VIAV icon
2639
Viavi Solutions
VIAV
$10.9B
$716K ﹤0.01%
68,134
+11,343
+20% +$137K
CTO
2640
CTO Realty Growth
CTO
$824M
$714K ﹤0.01%
39,076
+12,910
+49% +$248K
SABA
2641
Saba Capital Income & Opportunities Fund II
SABA
$222M
$714K ﹤0.01%
82,422
+2,576
+3% +$21.6K
DMLP icon
2642
Dorchester Minerals
DMLP
$1.37B
$713K ﹤0.01%
23,806
+4,264
+22% +$123K
MLCO icon
2643
Melco Resorts & Entertainment
MLCO
$2.19B
$712K ﹤0.01%
61,873
+8,594
+16% +$69.7K
FENY icon
2644
Fidelity MSCI Energy Index ETF
FENY
$2.1B
$710K ﹤0.01%
+29,764
New +$710K
MLP icon
2645
Maui Land & Pineapple Co
MLP
$311M
$709K ﹤0.01%
75,250
GMOM icon
2646
Cambria Global Momentum ETF
GMOM
$72.8M
$709K ﹤0.01%
25,019
-9,949
-28% -$286K
FFBW
2647
DELISTED
FFBW, Inc. Common Stock
FFBW
$705K ﹤0.01%
60,697
MYFW icon
2648
First Western Financial
MYFW
$308M
$704K ﹤0.01%
25,000
LAZ icon
2649
Lazard
LAZ
$4.42B
$699K ﹤0.01%
20,170
-820
-4% -$29.2K
PACB icon
2650
Pacific Biosciences
PACB
$354M
$699K ﹤0.01%
85,460
-9,630
-10% -$83K

Similar funds

Raymond James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Raymond James & Associates held 4,156 positions worth $109B, up 10% from $98.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Raymond James & Associates's Q4 2022 filing shows 227 new, 1,649 increased, 1,885 reduced and 242 closed positions. Its largest new stake was Rentokil: 285,133 shares worth $8.78M. The largest sale was iShares Expanded Tech Sector ETF, an estimated $79.2M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q4 2022 buy was Rentokil: 285,133 shares worth $8.78M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q4 2022, an estimated $169M increase.
  • Raymond James & Associates's biggest Q4 2022 reduction was iShares Expanded Tech Sector ETF, cutting an estimated $79.2M.
  • Raymond James & Associates fully exited Change Healthcare Inc. Common Stock in Q4 2022, selling an estimated $53.3M.
  • Raymond James & Associates's ten largest holdings make up 23% of its $109B portfolio in Q4 2022.
  • Raymond James & Associates opened 227 new positions and closed 242 in Q4 2022.
  • Raymond James & Associates's portfolio value rose 10% quarter-over-quarter to $109B.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.